Form 4: United Therapeutics CFO Executes Pre-Arranged Stock Option Exercise and Share Sale
Insider Transaction Report
James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), exercised stock options and subsequently sold common stock shares on June 2, 2025, as part of a pre-arranged 10b5-1 trading plan.
Summary
- James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), exercised 12,000 stock options at an exercise price of $117.76 per share on June 2, 2025.
- Following the option exercise, Mr. Edgemond sold a total of 12,000 shares of common stock in multiple transactions on the same date.
- The sales were executed at weighted average prices ranging from $325.5399 to $326.3393 per share.
- These transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan that was established on November 6, 2024.
- After these reported transactions, Mr. Edgemond beneficially owns 8,118 shares of common stock and 99,500 derivative stock options.
- Additionally, 50 shares of common stock were acquired on March 4, 2025, under the United Therapeutics Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While an insider sale might be perceived negatively, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates concerns about its implications for the company's immediate prospects. It represents a routine liquidity event for the executive.
Positives
- The exercise of stock options by the CFO indicates a realization of value from previously granted equity incentives.
- The transactions were conducted under a pre-arranged 10b5-1 plan, which suggests a systematic approach to managing personal holdings rather than a reaction to immediate company performance or undisclosed information.
Negatives
- The sale of 12,000 shares by a key executive, even under a 10b5-1 plan, reduces their direct ownership stake in the company's common stock.
Future Outlook
NA
Industry Context
This Form 4 filing details an executive's personal stock transactions and does not directly reflect broader industry trends. However, United Therapeutics operates within the biotechnology and pharmaceutical industry, focusing on developing and commercializing products for rare diseases.
Stakeholder Impact
- Shareholders: The sale of shares by a key executive, even if pre-arranged, could be interpreted by some as a slight reduction in insider ownership, though the 10b5-1 plan mitigates concerns about its implications for the company's immediate prospects.
Key Dates
| Date | Description |
|---|---|
| 03/15/2021 | Date stock options became exercisable. |
| 11/06/2024 | Date the pre-arranged 10b5-1 plan was entered into by the reporting person. |
| 03/04/2025 | Date 50 shares of common stock were acquired under the United Therapeutics Employee Stock Purchase Plan. |
| 06/02/2025 | Date of stock option exercise and subsequent sale of common stock. |
| 06/03/2025 | Date the Form 4 was signed. |
| 03/15/2027 | Expiration date of the exercised stock options. |
Recommendation
holdKeywords
United Therapeutics, UTHR, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Compensation, James Edgemond, CFO, Treasurer, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.